Randomized Trial of SGLT2i in Heart Transplant Recipients
Eligible age
18+ yrs
Accepts
All genders
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Heart transplant (HTx) is an established therapy for advanced heart disease that restores quality of life and improves survival. However, due to preexisting comorbidities combined with the immunosuppressive therapies required after transplantation, HTx recipients remain at high risk for kidney, cardiovascular (CV), and metabolic disease. Large randomized clinical trials have recently shown that sodium-glucose cotransporter 2 inhibitors (SGLT2i) have potent kidney protective and CV benefits in many populations of patients with chronic kidney disease (CKD), CV disease and/or diabetes. SGLT2i have not been studied prospectively in HTx recipients, which represents a barrier to their use in this population. In this multicenter randomized controlled trial in Veterans with HTx, investigators will evaluate the potential benefits of empagliflozin on kidney function, cardiometabolic risk, erythropoiesis, and functional status. A total of 200 Veterans will be randomly assigned to receive either empagliflozin 10 mg daily or a matching placebo for 12 months.
Sponsor: VA Office of Research and Development
You may qualify if…
- ✓ 1. Age 18 years or older
- ✓ 2. Heart transplant recipient, 3 months after transplant
You may not qualify if…
- ✕ 1. eGFR \<20 mL/min/1.73m2
- ✕ 2. Type 1 diabetes mellitus
- ✕ 3. HbA1C \>10%
- ✕ 4. Baseline UACR \<30 mg/g in patients without T2D
- ✕ 5. Known allergy or intolerance to SGLT2i
- ✕ 6. Active uncontrolled infection
- ✕ 7. Multiorgan transplant
- ✕ 8. SGLT2i treatment in the last 30 days
Where it's recruiting
Source: ClinicalTrials.gov · NCT06625073 · last updated 2026-01-22